[1] 范建高. 非酒精性脂肪性肝病的保肝药物治疗.中国临床医生,2011,39(4):74-75. [2] Fan JG,Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol,2009,50:204-210. [3] Delgado JS. Evolving trends in nonalcoholic fatty liver disease. Eur J Intern Med,2008,19:75-82. [4] Fan JG. Impact of nonalcoholic fatty liver disease on accelerated metabolic complications. J Dig Dis,2008,9:63-67. [5] de Alwis NM,Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol,2008,48:S104-112. [6] 中华医学会肝病学会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南(2010年修订版).中华肝脏病杂志,2010,18(3):163-166. [7] Feldstein AE,Gores GJ. Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci,2005,10:3093-3099. [8] Feldstein AE,Canbay A,Angulo P,et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology,2003,125:437-443. [9] Wieckowska A,Zein NN,Yerian LM,et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholicfatty liver disease. Hepatology,2006,44:27-33. [10] Younossi ZM,Jarrar M,Nugent C,et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg,2008,18:1430-1437. [11] Vos MB,Barve S,Joshi-Barve S,et al. Cytokeratin 18, a marker of cell death,is increased in children with suspected nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr,2008, 47:481-485. [12] Yilmaz Y,Ulukaya E,Dolar E. Serum M30 levels:a potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levels. Hepatology,2009,49:697. |